萬替妥單抗

化合物

萬替妥單抗INN:Vantictumab)是一種人IgG2單株抗體,設計用於治療癌症[1]

萬替妥單抗
單株抗體
種類?
目標捲曲受體
臨床資料
給藥途徑IV
ATC碼
  • 未分配
識別資訊
CAS號1345009-45-1
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6322H9722N1674O1988S46
摩爾質量142,461.81 g·mol−1

該藥物由OncoMed英語OncoMed製藥公司與拜耳合作開發。[2]OncoMed於2016年獲得專利,預計將於2029年到期。[3]2017年4月,拜耳終止了對萬替妥單抗的許可選擇。[4]

它通過靶向癌細胞上的捲曲受體來抑制wnt信號傳導。[5]

胰腺癌非小細胞肺癌乳腺癌的I期試驗已經完成。2016年報告了三陰性乳腺癌1b期臨床試驗的結果,[5][6]2020年報告了胰腺癌的1b期臨床試驗結果。[7]

參考資料

  1. ^ Statement on a nonproprietary name adopted by the USAN Council (PDF). AMA. 28 Nov 2012. N12/155.  
  2. ^ OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance. 12 January 2015 [2024-03-01]. (原始內容存檔於2024-03-01). 
  3. ^ Annual Report on Form 10-K. OncoMed Pharmaceuticals, Inc. (原始內容存檔於13 January 2017). 
  4. ^ BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept. Reuters. 10 April 2017 [2024-03-01]. (原始內容存檔於2021-05-18). 
  5. ^ 5.0 5.1 Finally, targeted therapies for triple-negative breast cancer. Medical Xpress. June 2016 [2024-03-01]. (原始內容存檔於2024-01-08). 
  6. ^ Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment. November 2020, 184 (1): 53–62. PMC 7572714 . PMID 32803633. doi:10.1007/s10549-020-05817-w. 
  7. ^ Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs. June 2020, 38 (3): 821–830. PMC 7211194 . PMID 31338636. doi:10.1007/s10637-019-00824-1.